Physician profile
Christopher M Smith
NPI 1952393829
$5,394.02
in general payments reported to CMS, 2019-2025
32 companies · $684 in 2025
The $684 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $619 · 2021: $750 · 2022: $682 · 2023: $1,063 · 2024: $1,102 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,848.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,384.36 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $464.87 | 2019-2025 | |
| Lilly USA, LLC | $420.49 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $337.10 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $323.27 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $305.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $301.77 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $292.65 | 2020-2025 | Winlevi, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $273.18 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $229.78 | 2019-2025 | Dupixent |
| Ucb, INC. | $172.67 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $114.05 | 2019-2025 | Nemluvio |
| Journey Medical Corporation | $109.83 | 2023-2025 | |
| Apyx Medical Corporation | $108.00 | 2019-2020 | |
| Almirall LLC | $62.26 | 2019-2023 | Seysara |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $58.05 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $49.57 | 2023 | Valchlor |
| Incyte Corporation | $48.78 | 2022-2023 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.35 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $36.29 | 2021 | |
| Arcutis Biotherapeutics, INC. | $33.78 | 2023-2024 | Zoryve |
| Organon LLC | $32.68 | 2025 | Vtama |
| Biocon Biologics INC | $28.90 | 2024 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.56 | 2023 | Spevigo |
| Revance Therapeutics, INC. | $20.00 | 2024 | Daxxify |
| Genentech USA, INC. | $19.82 | 2019 | |
| Botanix Sb INC | $19.27 | 2025 | Sofdra |
| Epi Health, LLC | $18.68 | 2019 | |
| Leo Pharma INC. | $16.77 | 2021 | |
| Prugen, INC. Pharmaceuticals | $15.68 | 2020 | |
| Convatec INC. | $15.14 | 2024 | |
| Mayne Pharma Commercial LLC | $14.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.